Precision BioSciences, Inc.

Approval AI-extracted

Azer-Cel

Diffuse Large B-Cell Lymphoma

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on Azer-Cel for Diffuse Large B-Cell Lymphoma is expected Date TBD.

Primary source · SEC 8-K verified 12h ago

“Precision received an $8 million milestone payment in the fourth quarter of 2025 as a result of Imugene’s progress with Azer-Cel.”